Artificial Intelligence in Cardiovascular Health: Insights into Post-COVID Public Health Challenges.

IF 2.9 Q2 PERIPHERAL VASCULAR DISEASE
Zayera Naushad, Jaya Malik, Abhishek Kumar Mishra, Shilpy Singh, Dharmsheel Shrivastav, Chetan Kumar Sharma, Ved Vrat Verma, Ravi Kant Pal, Biswajit Roy, Varun Kumar Sharma
{"title":"Artificial Intelligence in Cardiovascular Health: Insights into Post-COVID Public Health Challenges.","authors":"Zayera Naushad, Jaya Malik, Abhishek Kumar Mishra, Shilpy Singh, Dharmsheel Shrivastav, Chetan Kumar Sharma, Ved Vrat Verma, Ravi Kant Pal, Biswajit Roy, Varun Kumar Sharma","doi":"10.1007/s40292-025-00738-5","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) continue to be the topmost cause of the worldwide morbidity and mortality. Risk factors such as diabetes, hypertension, obesity and smoking are significantly worsening the situation. The COVID-19 pandemic has powerfully highlighted the undeniable connection between viral infections and cardiovascular health. Current literature highlights that SARS-CoV-2 contributes to myocardial injury, endothelial dysfunction, thrombosis, and systemic inflammation, increasing the severity of CVD outcomes. Long COVID has also been associated with persistent cardiovascular complications, including myocarditis, arrhythmias, thromboembolic events, and accelerated atherosclerosis. Addressing these challenges requires continued research and public health strategies to mitigate long-term risks. Artificial intelligence (AI) is changing cardiovascular medicine and community health through progressive machine learning (ML) and deep learning (DL) applications. AI enhances risk prediction, facilitates biomarker discovery, and improves imaging techniques such as echocardiography, CT, and MRI for detecting coronary artery disease and myocardial injury on time. Remote monitoring and wearable devices powered by AI enable real-time cardiovascular assessment and personalized treatment. In public health, AI optimizes disease surveillance, epidemiological modeling, and healthcare resource allocation. AI-driven clinical decision support systems improve diagnostic accuracy and health equity by enabling targeted interventions. The integration of AI into cardiovascular medicine and public health offers data-driven, efficient, and patient-centered solutions to mitigate post-COVID cardiovascular complications.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"475-494"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-025-00738-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiovascular diseases (CVDs) continue to be the topmost cause of the worldwide morbidity and mortality. Risk factors such as diabetes, hypertension, obesity and smoking are significantly worsening the situation. The COVID-19 pandemic has powerfully highlighted the undeniable connection between viral infections and cardiovascular health. Current literature highlights that SARS-CoV-2 contributes to myocardial injury, endothelial dysfunction, thrombosis, and systemic inflammation, increasing the severity of CVD outcomes. Long COVID has also been associated with persistent cardiovascular complications, including myocarditis, arrhythmias, thromboembolic events, and accelerated atherosclerosis. Addressing these challenges requires continued research and public health strategies to mitigate long-term risks. Artificial intelligence (AI) is changing cardiovascular medicine and community health through progressive machine learning (ML) and deep learning (DL) applications. AI enhances risk prediction, facilitates biomarker discovery, and improves imaging techniques such as echocardiography, CT, and MRI for detecting coronary artery disease and myocardial injury on time. Remote monitoring and wearable devices powered by AI enable real-time cardiovascular assessment and personalized treatment. In public health, AI optimizes disease surveillance, epidemiological modeling, and healthcare resource allocation. AI-driven clinical decision support systems improve diagnostic accuracy and health equity by enabling targeted interventions. The integration of AI into cardiovascular medicine and public health offers data-driven, efficient, and patient-centered solutions to mitigate post-COVID cardiovascular complications.

心血管健康中的人工智能:洞察后covid公共卫生挑战。
心血管疾病(cvd)仍然是世界范围内发病率和死亡率最高的原因。糖尿病、高血压、肥胖和吸烟等危险因素使情况明显恶化。2019冠状病毒病大流行有力地凸显了病毒感染与心血管健康之间不可否认的联系。目前的文献强调,SARS-CoV-2可导致心肌损伤、内皮功能障碍、血栓形成和全身炎症,增加心血管疾病结局的严重程度。长期COVID还与持续的心血管并发症有关,包括心肌炎、心律失常、血栓栓塞事件和动脉粥样硬化加速。应对这些挑战需要继续开展研究并制定公共卫生战略,以减轻长期风险。人工智能(AI)正在通过渐进式机器学习(ML)和深度学习(DL)应用改变心血管医学和社区健康。人工智能增强了风险预测,促进了生物标志物的发现,并改进了超声心动图、CT和MRI等成像技术,以及时检测冠状动脉疾病和心肌损伤。由人工智能驱动的远程监测和可穿戴设备实现了实时心血管评估和个性化治疗。在公共卫生领域,人工智能优化了疾病监测、流行病学建模和医疗资源分配。人工智能驱动的临床决策支持系统通过实现有针对性的干预措施,提高了诊断准确性和卫生公平性。将人工智能整合到心血管医学和公共卫生中,可提供数据驱动、高效和以患者为中心的解决方案,以减轻covid - 19后心血管并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
3.30%
发文量
57
期刊介绍: High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes:   Invited ''State of the Art'' reviews.  Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信